Gland Pharma
add_icon

Gland Pharma

1,626.60
-28.70
(-1.73%)
Market Cap
26,799.28 Cr
PE Ratio
32.21
Volume
1,11,001.00
Day High - Low
1,656.90 - 1,601.70
52W High-Low
2,131.00 - 1,277.80
ann
There are 1 new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
26,799.28 Cr
EPS
42.40
PE Ratio
32.21
PB Ratio
2.85
Book Value
580.41
EBITDA
1,482.50
Dividend Yield
1.09 %
Industry
Healthcare
Return on Equity
7.63
Debt to Equity
0.04
Analyst Rating and Forecast
- By Refinitiv from15 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+60.00 %
+60.00 %
Hold
Hold+13.33 %
+13.33 %
Sell
Sell+26.67 %
+26.67 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Gland Pharma Limited announces analyst and institutional investor meetings scheduled for March 18-20, 2026, including a Non-Deal Roadshow with Elara (USA) featuring one-on-one meetings.
negative
Gland Pharma receives GST tax demand order of INR 5.03 crores with penalty of INR 1.26 crores for FY 2019-20. Company plans to file appeal against the order.
positive
Gland Pharma receives tentative USFDA approval for Brimonidine Tartrate Eye Solution, matching Lumify Eye Solution with US sales projected at $39 million by September 2025.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,801.60
#1 4,32,264.19
39.98
#1 54,729.00
9.71
#1 10,980
16.07
62.14
6,071.00
1,61,165.97
67.21
9,712.00
18.67
2,191
-1.02
38.37
4,390.00
1,48,577.55
66.21
11,539.40
6.99
1,911
26.24
61.73
1,292.30
1,07,859.28
19.93
33,741.20
16.73
5,725
-15.28
51.79
1,314.70
1,06,197.76
23.61
28,409.50
7.12
5,291
-57.18
40.42
2,314.90
1,05,744.36
23.07
22,909.50
13.74
3,306
#1 37.44
57.99
905.90
91,154.74
#1 18.35
23,511.00
18.55
4,615
-0.32
48.43
2,138.90
88,294.88
50.56
12,744.20
#1 20.90
2,007
7.65
47.71
1,296.50
75,300.93
21.89
32,345.60
9.43
3,484
7.59
66.14
5,355.50
64,033.04
26.89
13,458.30
3.70
2,216
1.90
40.57
Growth Rate
Revenue Growth
-0.08 %
Net Income Growth
-9.58 %
Cash Flow Change
-8.23 %
ROE
-13.79 %
ROCE
-8.55 %
EBITDA Margin (Avg.)
-1.28 %

Quarterly Financial Results

Quarterly Financials
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
681
916
852
895
935
1,216
1,132
1,109
1,168
931
1,110
1,000
824
1,246
1,427
1,583
1,580
1,453
1,466
1,443
1,469
1,563
1,571
1,759
Expenses
395
472
534
595
560
718
704
714
755
587
748
649
673
915
1,049
1,189
1,179
1,137
1,109
1,024
1,077
1,138
1,173
1,285
EBITDA
286
445
318
299
375
498
428
395
414
344
363
351
151
332
377
394
401
316
357
418
392
425
398
474
Operating Profit %
38 %
47 %
36 %
31 %
37 %
38 %
35 %
33 %
32 %
32 %
28 %
31 %
14 %
24 %
24 %
23 %
23 %
19 %
21 %
26 %
24 %
24 %
21 %
24 %
Depreciation
24
24
25
25
25
25
26
28
31
35
37
38
38
65
81
105
93
92
94
96
96
101
106
108
Interest
1
1
1
1
1
1
1
1
2
1
2
3
2
5
6
5
10
6
6
23
7
12
8
4
Profit Before Tax
262
420
293
273
349
472
401
366
381
309
324
311
111
261
290
283
298
218
257
299
288
313
284
362
Tax
67
106
74
69
89
121
99
93
95
79
83
79
33
67
96
91
106
75
93
95
102
97
100
101
Net Profit
195
314
219
204
260
351
302
273
286
229
241
232
79
194
194
192
192
144
164
205
187
216
184
262
EPS in ₹
12.57
20.24
14.12
12.83
15.93
21.41
18.37
16.62
17.40
13.93
14.65
14.08
4.78
11.79
11.78
11.65
11.68
8.73
9.93
12.42
11.32
13.08
11.15
15.87

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
4,086
6,496
7,834
8,778
10,661
11,225
Fixed Assets
968
954
1,502
1,571
3,947
4,147
Current Assets
2,846
5,124
5,852
6,901
5,645
6,783
Capital Work in Progress
189
338
191
177
238
151
Investments
0
0
155
0
0
0
Other Assets
2,930
5,204
5,986
7,030
6,477
6,927
Total Equity & Liabilities
4,086
6,496
7,834
8,778
10,661
11,225
Current Liabilities
359
513
582
729
1,398
1,565
Non Current Liabilities
81
80
94
90
539
509
Total Equity
3,646
5,903
7,158
7,959
8,724
9,151
Reserve & Surplus
3,631
5,887
7,141
7,942
8,707
9,134
Share Capital
16
16
16
17
17
17

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
-67
323
-174
1,590
-1,552
2,199
Investing Activities
-761
-1,520
-999
1,211
-1,749
1,718
Operating Activities
701
605
791
364
997
915
Financing Activities
-7
1,239
35
15
-799
-434

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
58.25 %
58.14 %
58.02 %
58.00 %
58.00 %
57.87 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
57.86 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
51.83 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.00 %
4.91 %
0.00 %
3.59 %
6.88 %
4.47 %
5.04 %
6.90 %
7.39 %
7.91 %
7.58 %
DIIs
10.69 %
11.57 %
11.39 %
11.21 %
11.94 %
16.71 %
20.58 %
23.13 %
23.23 %
23.38 %
22.45 %
23.14 %
25.23 %
32.83 %
35.37 %
34.80 %
33.27 %
32.85 %
32.64 %
32.98 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
3.30 %
3.72 %
3.77 %
3.58 %
3.69 %
3.70 %
3.77 %
4.02 %
4.26 %
5.60 %
4.52 %
3.79 %
3.28 %
3.33 %
3.28 %
3.30 %
2.99 %
2.91 %
2.57 %
2.57 %
Others
27.76 %
26.58 %
26.81 %
27.21 %
26.37 %
21.71 %
17.78 %
14.98 %
14.64 %
13.16 %
10.27 %
15.22 %
10.04 %
5.12 %
5.04 %
5.04 %
5.01 %
5.02 %
5.06 %
5.04 %
No of Share Holders
84,467
98,203
1,09,326
1,09,097
1,09,098
1,17,339
1,27,879
1,48,469
1,50,578
1,81,747
1,61,627
1,36,021
1,22,375
1,22,665
1,22,358
1,21,075
1,13,788
1,10,671
97,151
94,578

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20 18 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.26 1.11 0.00

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation5 days ago
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 20158 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)Mar 03, 2026
Announcement under Regulation 30 (LODR)-Issue of SecuritiesMar 03, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 25, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 18, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 09, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 06, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 03, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 01, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJan 29, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 29, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 28, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJan 28, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2026
Board Meeting Outcome for Outcome Of Board Meeting Held On January 28 2026Jan 28, 2026
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025Jan 28, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 13, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 09, 2026
Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025Jan 09, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 07, 2026
Closure of Trading WindowDec 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 04, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 03, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 03, 2025
Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 03, 2025
Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Nov 03, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 31, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 17, 2025
Board Meeting Intimation for Declaration Of Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025Oct 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Closure of Trading WindowSep 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 17, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 08, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 28, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateAug 28, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 28, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 28, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 26, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.76%
935
-0.02%
0.07%
JioBlackRock Sector Rotation Fund Direct - Growth
0.10%
614
0.10%
0.10%
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth
1.62%
116
-0.01%
0.16%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
0.76%
38
-0.01%
0.08%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.25%
-19
-0.01%
0.02%
DSP Nifty 500 Index Fund Direct-Growth
0.07%
-3
-0.01%
0.07%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.07%
2
0.00%
0.01%
Kotak Healthcare Fund Direct - Growth
2.58%
0
0.00%
-0.23%
Axis Multicap Fund Direct-Growth
0.43%
0
0.00%
-0.02%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.75%
0
0.00%
-0.02%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth
1.07%
0
0.00%
-0.07%
Aditya Birla Sun Life Quant Fund Direct-Growth
0.00%
0
0.00%
0.00%
Angel One Nifty Total Market Index Fund Direct - Growth
0.07%
0
0.00%
0.00%
Axis ESG Integration Strategy Fund Direct-Growth
4.66%
0
0.00%
0.02%
Axis India Manufacturing Fund Direct-Growth
0.49%
0
0.00%
-0.03%
Axis Large & Mid Cap Fund Direct-Growth
0.30%
0
0.00%
-0.01%
Kotak Nifty Smallcap 50 Index Fund Direct - Growth
2.01%
0
0.00%
-0.05%
Axis Nifty 500 Index Fund Direct-Growth
0.07%
0
0.00%
0.00%
Axis Nifty Smallcap 50 Index Fund Direct-Growth
2.00%
0
0.00%
-0.06%
Axis Small Cap Fund Direct-Growth
0.32%
0
0.00%
-0.01%
Bandhan BSE Healthcare Index Fund Direct-Growth
1.06%
0
0.00%
-0.08%
Bandhan Large & Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Nifty Midcap 150 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.76%
0
0.00%
-0.01%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.07%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
30.60
ATR(14)
Less Volatile
57.03
STOCH(9,6)
Oversold
17.28
STOCH RSI(14)
Oversold
1.80
MACD(12,26)
Bearish
-19.81
ADX(14)
Weak Trend
22.98
UO(9)
Bearish
41.17
ROC(12)
Downtrend And Accelerating
-9.75
WillR(14)
Oversold
-90.88

About Gland Pharma

Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs....more
Listing Date
20 Nov, 2020(5 Years, 22 days)
Chairperson NameSRINIVAS SADU